Skip to main content
OpenTrials
Completed

NCT Number: NCT03886909

Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant

The purpose of this study is to determine whether patients are able to participate in a prehabilitation program (prior to the beginning of treatment) which includes: (1) a home-based exercise program or (2) just a prehabilitation education session.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Penn State Cancer Institute

Hershey, Pennsylvania, 17033, United States

About this study

Hematopoietic stem cell transplant may have the potential for severe side effects, including functional (reduced aerobic capacity, reduced muscle strength) and psychosocial (e.g. reduced quality of life, increased fatigue) detriments.

Evidence shows that exercise is considered to be an effective treatment approach in hematopoietic stem cell transplant patients during and after treatment with regard to the above mentioned side-effects. Also, prehabilitative exercise in colon and lung cancer patients was shown as feasible and effective. However, no experience exists with regard to prehabilitation exercise in hematopoietic stem cell transplant patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hematological cancer (e.g. Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, etc.)
  • Hematological cancer in remission
  • Females and males ≥18 years of age
  • Fluent in written and spoken English
  • Must be able to provide and understand informed consent
  • Must have an ECOG score of ≤ 2
  • Scheduled for an inpatient autologous or allogeneic stem cell transplant at Penn State Cancer Institute
  • ≥ 2 weeks until scheduled transplant
  • Primary attending physician approval

Exclusion criteria

  • Hematological cancer not in remission
  • Evidence in the medical record of an absolute contraindication (e.g. Heart insufficiency > NYHA III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability) for exercise
  • Any other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist
  • Uncontrolled hypertension
  • Receiving non-transplant related chemotherapy and/or radiotherapy
  • Not fluent in written and spoken English
  • Active infections, hemorrhages, and cytopenias that could place transplant patients at risk for further adverse events, deemed by the exercise interventionist, physician and/or nurse

Treatment and study plan

Exercise

Behavioral

The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).

Prehabilitation Education

Behavioral

Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.

Primary outcomes

  1. Feasibility of the exercise intervention: 50% of included patients actually complete at least one third of the exercise sessions

    Time frame: Through study completion, an average of 18 months

    The exercise intervention will be considered feasible if 50% of included patients actually complete at least one third of the exercise sessions prescribed for 2 weeks or more.

  2. Acceptability of the exercise intervention: more than 50% of the patients approached

    Time frame: During recruitment

    The exercise intervention will be considered acceptable if more than 50% of the patients approached agree to receive at least the first exercise session.

  3. Safety of the exercise intervention: questionnaire

    Time frame: Through the study completion, an average of 18 months

    Within the questionnaire we will assess whether musculoskeletal occur (yes/no; ongoing; location; severity (mild-life threatening); daily activities affected). The intervention will be considered as safe if less than 25% of included patients report mild musculoskeletal impairments and less than 5% experienced musculoskeletal injuries (defined as symptoms lasting a week or longer and or requiring the attention of a medical professional).

Secondary outcomes

  1. Health-related Quality of Life: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0)

    Time frame: Through study completion, an average of 18 months

    QoL will be assessed with the validated 30-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0).

    The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

  2. Bone Marrow Transplant-related Quality of Life: EORTC QLQ-HDC29

    Time frame: Through study completion, an average of 18 months

    Quality of Life will be assessed with the validated 29-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- High Dose Chemotherapy- 29 Items (EORTC QLQ-HDC29).

    The QLQ HDC29 module includes 29 items, consisting of six multi-item scales and eight single-items. For the multi-item scales and single-item scales a high score is equivalent to worse or more symptoms/problems.

  3. Fatigue

    Time frame: Through study completion, an average of 18 months

    Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI) which is a 20-item, multidimensional self-assessment questionnaire.

    Respondents use a scale ranging from 1 to 7 to indicate how aptly certain statements regarding fatigue represent their experiences. Higher total scores correspond with more acute levels of fatigue.

  4. Sleep

    Time frame: Through study completion, an average of 18 months

    Sleep quality and sleep problems will be assessed with the validated and frequently used Pittsburgh Sleep Quality Index (PSQI).

    In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

  5. Depression

    Time frame: Through study completion, an average of 18 months

    Depressive symptoms will be assessed with the 20-item Center for Epidemiological Studies Depression Scale (CES-D).

    Zero for 'Rarely', 1 for 'Some or a little of the time', 2 for 'Occasionally or a moderate amount of time', 3 for 'Most or all of the time'. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.

  6. Short Questionnaire to Assess Health-Enhancing Physical Activity

    Time frame: Through study completion, an average of 18 months

    Physical activity behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Short QUestionnaire to ASsess Health-enhancing Physical Activity (SQUASH).

    Household work and activities at work or school were prestructured for intensity. A basic intensity score of 2 and 5 for light and intense activities, respectively. Total minutes of activity are calculated for each question by multiplying frequency (days/week) by duration (min/day). Activity scores for separate questions are calculated by multiplying total minutes of activity by the intensity score. The total activity score is calculated by taking the sum of the activity scores for separate questions. Higher values equals more time spent completing the activity.

  7. Godin Physical Activity Questionnaire

    Time frame: Through study completion, an average of 18 months

    Physical activity behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Godin Physical Activity Questionnaire.

    Total weekly leisure activity is calculated in arbitrary units by summing the products of the separate components, as shown in the following formula:

    Weekly leisure activity score = (9 × Strenuous) + (5 × Moderate) + (3 × Light) Higher activity score = more active

  8. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

    Time frame: Through study completion, an average of 18 months

    Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) will be used to collect information on severity and interference of symptoms and adverse events.

  9. Body Pain: Brief Pain Inventory- Short form

    Time frame: Through study completion, an average of 18 months

    Bodily pain will be assessed using the Brief Pain Inventory- Short form (BPI-SF).

    The BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score is calculated from the four items about pain intensity. Each item is rated from 0, no pain, to 10, pain as bad as you can imagine, and contributes with the same weight to the final score, ranging from 0 to 40. The pain interference score corresponds to the item on pain interference. The seven sub-items are rated from 0, does not interfere, to 10, completely interferes, and contributes with the same weight to the final score, ranging from 0 to 70.

  10. Physical Function: Short Physical Performance Battery

    Time frame: Through study completion, an average of 18 months

    Objectively-measured physical function will be assessed using the Short Physical Performance Battery (SPPB).

    The SPPB is an accumulation of balance tests, 4-meter gait speed, and 5-chair stands. Based on the time needed to complete the chair stands, a score is given. A summation of scores from all tests is taken, ranging from 0 -12. A higher score = Higher physical function.

  11. Aerobic Capacity: Six Minute Walk Test

    Time frame: Through study completion, an average of 18 months

    Objectively-measured physical function will be assessed using the Six Minute Walk Test (6MWT).

    Distance walked during 6 minutes (measured in meters) is measured. Longer distance = higher aerobic capacity.

  12. Physical Function: Timed-Up-and-Go Test

    Time frame: Through study completion, an average of 18 months

    Objectively-measured physical function will be assessed using the Timed-Up-and-Go test (TUG).

    Time taken to stand up from a chair, walk 10 meters around an obstacle, and return to seated position is measured in seconds. Lower time = better physical function.

  13. Fall Risk

    Time frame: Through study completion, an average of 18 months

    Functional balance will be assessed using the Berg Balance Scale.

    Scoring: A five-point ordinal scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Score is summation of all items. Highest Total Score = 56 Interpretation: 0-20: Wheelchair bound; 21-40: Walking with assistance; 41-56: Independent

Sponsors and collaborators

Lead sponsor

Milton S. Hershey Medical Center

Other

Registry information

Official study title

The Effects of a Prehabilitation Exercise Program in Adults Receiving a Hematopoietic Stem Cell Transplant

Acronym: IMPROVE-BMT

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Mar 22, 2019
Registry last updated
Jul 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.